Back to Search Start Over

Boehringer Ingelheim's latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis

Source :
PR Newswire. May 15, 2022
Publication Year :
2022

Abstract

- Promising 12-week Phase II trial data with BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, published in The New England Journal of Medicine - Potential new treatment for [...]

Details

Language :
English
Database :
Gale General OneFile
Journal :
PR Newswire
Publication Type :
News
Accession number :
edsgcl.703838391